20th Nov 2013 10:55
LONDON (Alliance News) - Proteome Sciences PLC said Wednesday that a study conducted in partnership with the Kings College Hospital NHS Foundation Trust has showed the discovery and validation of new protein biomarkers for patient stratification in liver cancer using its proteomic workflows.
Patient stratification is the process of using biomarkers, indicators of a condition or disease, to provide more details about how a patient will respond to a drug before a clinical trial.
The discovery of biomarkers have helped to define the sub-types of liver cancer which require different treatment options.
Proteome Sciences focuses on biomarker research and development in the large-scale study of proteins, also known as proteomics. The study was conducted using the company's PS Biomarker Services.
"Stratified medicine is a key component of the global response to major healthcare challenges that urgently requires new biomarkers to guide early diagnosis and treatment selection," said Chief Operating Officer Ian Pike in a statement. "The results from this study show the value of Proteome Sciences' proteomics technologies in discovering and validating biomarkers for stratified medicine in liver cancer."
Shares in Proteome Sciences were trading up 2.4% at 41.33 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Proteome